Immunogenicity of immune checkpoint inhibitors: Implications for clinical practice

touchPANEL DISCUSSION for touchONCOLOGY Listen to a panel of leading experts discuss the clinical relevance of the immunogenicity of immune checkpoint inhibitors for the treatment of cancer, informed by experience in inflammatory diseases. The experts: Prof. Peter Galle, University of Mainz, Germany, Dr Victor Moreno, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain, Dr Vibeke Strand, Stanford University School of Medicine, Palo Alto, CA, USA.  This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.   For further information visit our website: https://touchoncologyime.org/immune-checkpoint-inhibitors-immunogenicity/